Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a subcutaneous induction regimen of guselkumab for the treatment of adults with moderately ...

The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.

Tom Cruise’s Ray-Bans in “Top Gun.” The trail of Reese’s Pieces E.T. follows into the bedroom. That Vespa Jennifer Coolidge rides while cruising through Sicily in “The White Lotus.” cruising through ...

Though the PRAETORIAN group was technically unable to prove that 8 years was enough to give a subcutaneous implantable cardioverter-defibrillator (ICD) an edge in safety, complication rates helped ...

Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer ...

Among recipients of subcutaneous implantable cardioverter defibrillators, the omission of defibrillation testing (DT) was not associated with significant differences in mortality, or in the rates of ...

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...